Cresco Labs Stock Price, News & Analysis

Cresco Labs (CRLBF) has announced an updated schedule for its first quarter 2025 earnings release. The company will file its Q1 interim financial statements and MD&A on Friday, May 30, 2025. Following a three-week review period with independent auditors, Cresco confirmed no material changes were found from the preparation made for May 9th.

The earnings conference call and webcast is scheduled for Monday, June 2, 2025, at 8:30 am ET. The webcast recording will be accessible for one year through Cresco Labs' investor relations website.

Cresco Labs (CRLBF) has announced the grand opening of a new Sunnyside dispensary in Chippewa Township, Beaver Falls, Pennsylvania. The dispensary, located at 2634 Darlington Road, is strategically positioned just 1.5 miles northwest of I-376, making it easily accessible to patients from nearby towns including New Brighton, West Mayfield, and New Beaver.

According to CEO Charlie Bachtell, Pennsylvania remains a standout market for Cresco Labs, where the company holds the #1 position in branded market share. The new location demonstrates Cresco's strategy of deepening its presence in core states while leveraging its strong retail presence. The dispensary will operate Sunday through Thursday from 9 a.m. to 6 p.m., and Friday and Saturday from 9 a.m. to 7 p.m.

Cresco Labs (CRLBF) has announced the postponement of its Q1 2025 earnings call, originally scheduled for May 9, 2025. The company needs additional time to complete the review procedures for its first quarter interim financial statements. The cannabis company expects to host the rescheduled earnings call and file its Q1 interim financial statements by the required filing deadline of May 30, 2025. A new earnings call date will be announced once determined.

Cresco Labs, a leading cannabis products company and operator of Sunnyside dispensaries, has scheduled its first quarter 2025 financial results announcement for May 9, 2025, before market opening.

The company will host a conference call and webcast at 8:30 am ET to discuss Q1 2025 performance and highlight key business developments. Investors can participate through multiple channels:

• US Toll-Free: 1-833-470-1428
• US Local: 1-404-975-4839
• Access Code: 671160

The webcast recording will remain accessible for one year through Cresco Labs' investor relations website. The company, which trades on multiple exchanges (CSE:CL, OTCQX:CRLBF, FSE:6CQ), maintains its position as an industry leader in branded cannabis products across America.

Cresco Labs reported strong financial results for 2024, achieving record operating cash flow of $132 million, up 126% year-over-year. The company generated annual revenue of $724 million with an Adjusted EBITDA of $200 million, increasing 15% from the previous year.

Key financial highlights include gross profit of $364 million, adjusted gross margin of 52% (improving 270 bps), and reduced Adjusted SG&A by 12% to $212 million. The company reported a net loss of $60 million, including one-time non-cash charges of $66 million related to 280E position benefits.

Cresco maintained market leadership as the No. 1 share position in Illinois, Pennsylvania, and Massachusetts throughout 2024. The company ended the year with $141 million in cash and announced expansion into Kentucky as one of only two Tier 3 cultivators, with up to 25,000 square feet of canopy representing over 20% of the state's total allocation.

Cresco Labs has secured a management services agreement for a Tier 3 Cultivation License in Kentucky, becoming one of only two operators with this coveted license type. The agreement allows Cresco to manage and operate a cultivation facility with up to 25,000 square feet of canopy.

Kentucky's medical cannabis program, which launched on January 1, 2025, includes a total of 115,000 square feet of approved canopy space and 48 retail licenses. Industry analysts project the market to generate over $135 million in revenue by 2026, expanding to more than $228 million by 2028.

CEO Charlie Bachtell emphasized that this expansion represents the company's first opportunity to reinvest free cash flow into high ROIC growth initiatives, following two years of core business solidification.

Cresco Labs (CSE:CL) (OTCQX:CRLBF), a leading branded cannabis products company and operator of Sunnyside dispensaries, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 12, 2025, before market opening.

The company will host an earnings conference call and webcast at 8:30 am ET on the same day. Investors can access the call through US Toll Free (1-833-470-1428) or US Local (1-404-975-4839) numbers using access code 680910. The webcast recording will remain accessible for one year on Cresco Labs' investor relations website.

Cresco Labs reported strong Q3 2024 financial results, highlighting record quarterly operating cash flow of $49 million and year-to-date operating cash flow of $103 million, up 66% year-over-year. The company achieved $180 million in revenue with an Adjusted EBITDA of $51 million, representing a 5% year-over-year increase. The quarter showed a 29% Adjusted EBITDA margin, improving 280 basis points year-over-year. Cresco maintained market leadership positions in Illinois, Pennsylvania, and Massachusetts while advancing to top 3 in Ohio. Despite recording a net loss of $8 million, the company demonstrated strong cash management with $157 million in cash and equivalents.